Revumenib
- Generic Name
- Revumenib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47FN6O4S
- CAS Number
- 2169919-21-3
- Unique Ingredient Identifier
- LZ0M43NNF2
- Associated Conditions
- -
- Associated Therapies
- -
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT05731947
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, Manhattan, New York, United States
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT05406817
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT05326516
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of California, San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 413
- Registration Number
- NCT04065399
- Locations
- 🇫🇷
Hospital Saint-Louis - APHP, Paris, France
🇫🇷Centre Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France
🇩🇪University Hospital Of Ulm, Universitatsklinikum Ulm, Ulm, Baden-Württemberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.